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Thrombocytosis is a commonly encountered clinical scenario, with a large proportion of cases discovered incidentally. The
diﬀerential diagnosis for thrombocytosis is broad and the diagnostic process can be challenging. Thrombocytosis can be
spurious, attributed to a reactive process or due to clonal disorder. This distinction is important as it carries implications for
evaluation,prognosis,andtreatment. Clonalthrombocytosis associatedwith themyeloproliferativeneoplasms,especially essential
thrombocythemia and polycythemia vera, carries a unique prognostic proﬁle, with a markedly increased risk of thrombosis.
This risk is the driving factor behind treatment strategies in these disorders. Clinical trials utilizing targeted therapies in
thrombocytosis are ongoing with new therapeutic targets waiting to be explored. This paper will outline the mechanisms
underlying thrombocytosis, the diagnostic evaluationof thrombocytosis, complications of thrombocytosis with a special focus on
thrombotic risk as well as treatment options for clonal processes leading to thrombocytosis, including essential thrombocythemia
and polycythemia vera.
1.Diagnostic EvaluationofThrombocytosis
The threshold for clinically signiﬁcant thrombocytosis is
variable from patient to patient, and the exact deﬁnition
of thrombocytosis also varies in the literature, although a
platelet count of ≥450 × 109/L is a generally accepted value
[1]. A cohort study evaluating 10,000 Italian patients found
a platelet count greater than 409 × 109/L for women and
381 × 109/L for men represented the 99th percentile in this
population [2]. In this cohort, 99 patients (0.99%) had a
plateletcountgreaterthan400 ×109/Lonﬁrstmeasurement,
with only 8 of these 99 exhibiting persistent thrombocytosis
on re-evaluation 8 months later, reinforcing the importance
of re-evaluation for persistence of thrombocytosis. Throm-
bocytosis has a multitude of potential etiologies and thus
evaluation of a patient with thrombocytosis requires careful
consideration of patient history, comorbid conditions, other
hematologic parameters, and past platelet counts. In general,
causes of thrombocytosis can be described as spurious,
reactive, or clonal in nature (Table 1)[ 3].
A number of population studies have examined the
degree of thrombocytosis as well as the frequency of various
etiologies of thrombocytosis when it occurs. Reactive causes
are by far the most common etiology of thrombocytosis in
these population studies, comprising 88–97% of cases in
adults in two large case series [4, 5] and 100% of pediatric
cases in a single case series [6]. Extreme thrombocytosis,
deﬁned as a platelet count >1,000 × 109/L is quite rare,
as only 2–5.8% of patients demonstrate this degree of
thrombocytosis upon presentation [4–6]. Although often
thought to be more common in clonal processes, extreme
thrombocytosis can also be due to reactive causes, with
82% of cases of extreme thrombocytosis in one series being
reactive in nature [7].
1.1. SpuriousThrombocytosis. Spuriousthrombocytosis isan
extremely rare cause of apparent thrombocytosis, although
it is likely underrecognized and characterized as reactive
thrombocytosis in many cases as it often occurs along2 Thrombosis
Table 1: Causes of thrombocytosis (adapted from Harrison et al.).
Clonal Reactive Spurious
Essential thrombocythemia Infection Microspherocytes
Polycythemia vera Inﬂammation Cryoglobulinemia
Primary myeloﬁbrosis Tissue damage Neoplastic cell fragments
Myelodysplasia with del (5q) Hyposplenism Schistocytes
Refractory anemia with ringed Post-operative Bacteria
sideroblasts associated with
marked thrombocytosis (RARS-T)
Chronic myeloid leukemia Iron deﬁciency
Chronic myelomonocytic leukemia Malignancy
Atypical chronic myeloid leukemia Hemolysis
MDS/MPN-U Drug eﬀect
POEMS syndrome “Rebound” following myelosuppression
Familial thrombocytosis
with processes associated with reactive thrombocytosis.
Spurious thrombocytosis is characterized by the presence
of nonplatelet structures in the peripheral blood which are
counted as platelets by the automated counters used in
modern complete blood counts. A variety of such structures,
including needle-like cryoglobulin crystals [8], cytoplasmic
fragments ofcirculating leukemiccells[9], bacteria[10], and
red blood cell microvesicles following massive burn injury
[11] are examples of the wide variety of structures that can
mimic platelets when analyzed by automated cell counters.
Peripheral blood smear evaluation is a simple method
to conﬁrm the veracity of a diagnosis of thrombocytosis
and should be a part of every evaluation for a cause of
thrombocytosis.
1.2. Reactive Thrombocytosis. Once the diagnosis of throm-
bocytosis is conﬁrmed by peripheral blood smear review,
the diagnostic evaluation turns to determining whether
the process is reactive or clonal in nature (Figure 1). An
importantinitialstepinthisdeterminationisfamiliarity with
the underlying causes of reactive thrombocytosis (Table 1).
In adults, infection (typically acute), tissue damage, chronic
inﬂammatory disorders, and malignancy are the most com-
mon causes of reactive thrombocytosis, with one or more
of these processes present in >75% of cases of reactive
thrombocytosis [4, 5]. In children, the most common causes
of reactive thrombocytosis are similar, although hemolytic
anemias, especially thalassemia, were a relatively common
etiology in at least one Middle Eastern study [6]. A thorough
history and physical examination should allow for the
exclusion of multiple of the most common causes of reactive
thrombocytosis.
The presence of a potential cause of reactive throm-
bocytosis does not rule out a concomitant clonal process,
especially in persistent thrombocytosis. Much work has been
done in an eﬀort to come up with aﬀordable, reliable, and
rapid laboratory evaluation which can distinguish clonal
processes from reactive thrombocytosis. The basis of many
of these proposed evaluations is based on the mechanisms of
reactive thrombocytosis.
Thrombocytopoiesis occurs in the setting of a complex
cytokine milieu. Thrombopoietin (TPO) is the primary
regulator of platelet production [12, 13], but many other
cytokines such as IL-1 [14–16], IL-4 [17], IL-6 [14–
22], IL-11 [23], and TNF [15] play important roles in
thrombocytopoiesis. Many of these same cytokines also
play a critical role in the body’s response to inﬂammatory
conditions [24, 25]. Evaluation of patients with reactive
and clonal thrombocytosis has consistently demonstrated
that circulating levels of multiple cytokines, most notably
IL-6 [14, 17, 19, 20, 22, 25, 26] are elevated in patients
with reactive thrombocytosis but not in those with clonal
thrombocytosisornormal controls. Evaluationofcirculating
thrombopoietinlevelsasadiscriminant betweenreactiveand
clonal processes has proved less informative, as results have
not been consistent [18, 21, 22, 25–28]. One diﬃculty in
utilizing circulating cytokine levels as a diagnostic tool lies
in the ﬁnding thatthe rise in cytokinelevelsseems to precede
the clinical ﬁnding of thrombocytosis, with levels returning
to normal or near normal by the time thrombocytosis occurs
[18, 21]. This fact, along with the diﬃculty in bringing such
t e s t st oc l i n i c a lu s e ,h a sl e dt oas e a r c hf o rs u r r o g a t em a r k e r s
which may correlate with elevated cytokine levels, especially
IL-6. Many other markers of the acute phase reaction,
including C-reactive protein (CRP) [14, 19], ferritin [14],
and erythrocyte sedimentation rate (ESR) [14], are also
signiﬁcantly elevated in patients with reactive as opposed to
clonal thrombocytosis.
Teﬀeri et al. [19] showed a correlation between IL-6 and
CRP levels in a study of 91 patients with thrombocytosis,
regardless of etiology. 76% of patients in this study with
reactive thrombocytosis had an elevated CRP (>1.0mg/dL),
compared to 10% of patient with clonal thrombocytosis.
Thus, measurement of CRP and other acute phase reactants
can serve as easily obtained surrogates for measurement of
cytokines important in thrombocytopoiesis and should be
a part of any evaluation where reactive thrombocytosis is
suspected. These surrogates are neither sensitive nor speciﬁcThrombosis 3
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Figure 1: Diagnostic algorithm (Adapted from Harrison et al. and Teﬀeri et al.). BM Bx: bone marrow biopsy; CML: chronic myelogenous
leukemia; Epo: serum erythropoietin; ET: essential thrombocythemia; MDS: myelodysplastic syndrome; PMF: primary myeloﬁbrosis; PV:
polycythemia vera.
enough to allow them to play a deﬁnitive diagnostic role,
but elevated acute phase reactants can support a diagnosis
of reactive thrombocytosis in the right clinical setting.
Other methods evaluated as ways to delineate reactive from
clonal thrombocytosis include platelet indices [29], platelet
function testing [30], and gene expression proﬁling [31].
Iron deﬁciency anemia is a common cause of reactive
thrombocytosis [32], and evaluation of ferritin and iron
studies should be a part of the evaluation of every patient
with suspected reactive thrombocytosis. The pathophysiol-
ogy of reactive thrombocytosis in iron deﬁciency anemia
remains incompletely understood. Akan et al. demonstrated
that levels of a number of cytokines typically elevated in
reactive thrombocytosis (IL-6, IL-11, and TPO) were not
elevated in patients with iron deﬁciency and thrombocytosis
when compared to iron-deﬁcient patients with normal
platelet counts [33] .T h el e v e l so ft h e s ec y t o k i n e sd i dn o t
change with iron therapy and resolution of thrombocytosis,
indicating they likely do not play a major role in iron-
deﬁciency-related thrombocytosis. The only hematopoietic
cytokine found to be signiﬁcantly elevated in this cohort was
erythropoietin (EPO), which was elevated in patients with
and without thrombocytosis.
The role EPO plays in iron-deﬁciency-related throm-
bocytosis has garnered much interest, as administration of
human recombinant EPO (rh-EPO) results in thrombocy-
tosis of varying degree and duration in healthy controls
[34] as well as patients with chronic kidney disease [35].
The physiology underlying this ﬁnding is controversial, as
rh-EPO administration often leads to iron deﬁciency [36],
leading to diﬃculty in determining whether elevated or
exogenous EPO is a cause of thrombocytosis or simply
a surrogate for iron deﬁciency. Studies, however, have
consistently shown an increase in platelet count within 5
days of initiation of rh-EPO therapy [34, 35] regardless of
serum ferritin levels [35], indicating a probable role for EPO
in increasing platelet count independent of its eﬀect of iron
stores. It has been suggested that homology between the
receptor for EPO (EPO-R) and TPO (MPL) may underlie
this EPO-induced platelet rise [37], but in vitro studies have
shown that EPO does not interact directly with MPL [38]
and more likely plays a synergistic role along with TPO in
stimulating platelet production [39, 40].
As this discussion demonstrates, the pathophysiology of
reactive thrombocytosis is varied and complex. Even with
all the diagnostic tools currently available, the diagnosis
ultimately remains a clinical one based on laboratory ﬁnd-
ings, determination of a likely underlying cause, and, when
possible, improvement with treatment of the underlying
cause.4 Thrombosis
1.3. Clonal Thrombocytosis. Once a reactive thrombocytosis
is excluded and thrombocytosis is persistent, the diagnostic
evaluationshould turnto distinguishing betweenthevarious
causes of clonal thrombocytosis (Figure 1). The “clas-
sic” myeloproliferative neoplasms (MPNs), comprised of
essential thrombocythemia (ET), chronic myeloid leukemia
(CML), polycythemia vera (PV), and primary myeloﬁbrosis
(PMF)[41]arethemostcommonclonalprocessesassociated
with thrombocytosis. This group of diseases is characterized
by clonal expansion of a particular lineage of mature and/or
maturing myeloid cells that arise from a hematopoietic
stem cell. The 2008 World Health Organization (WHO)
classiﬁcation of Haematopoietic and Lymphoid Tissues [42]
provides criteria for the diagnosis of all four “classic” MPNs,
which are summarized in Figure 2.
CML is characterized by dysregulated clonal expansion
of all cells along the granulocytic maturation pathway.
The etiologic abnormality and cornerstone for diagnosis
of CML is the “Philadelphia chromosome”—a balanced
translocation between chromosomes 9 and 22 leading to
fusion of the BCR and ABL1 genes and BCR-ABL1 fusion
protein [43]. This translocation and resultant fusion protein
is found in all patients with CML and can be detected by
cytogenetics, ﬂuorescence in situ hybridization (FISH), or
reverse-transcriptase polymerase chain reaction (RT-PCR)
[42]. Approximately 50% of patients with CML will present
with thrombocytosis [44], usually in concert with a marked
leukocytosis composed of cells in all phases of granulocytic
maturation.However,asmallnumberofpatientswillpresent
with only mild or absent leukocytosis and thrombocytosis as
the only hematologic abnormality [44], making evaluation
for BCR-ABL1 an essential component of any evaluation of
clonal thrombocytosis, given the implications for manage-
ment and prognosis a diagnosis of CML carries.
Discovery of BCR-ABL1 fusion in CML served as evi-
dence of clonality in this disease and led to a vigorous
search for clonal molecular markers in the “Philadelphia
chromosome negative” (Ph-) MPNs. This search has led
to the discovery of multiple mutations crucial to our
understanding of these disorders. The ﬁrst of these discov-
eries occurred in 2005, when multiple independent groups
describedan acquiredpoint mutationin exon14oftheJanus
kinase 2 (JAK2) gene resulting in a valine to phenylalanine
substitution at codon 617 (JAK2V617F)[ 45–49]. JAK2 is
a cytoplasmic tyrosine kinase with an important role in
signal transduction in response to hematopoietic growth
factors [50–52]. The JAK2V617F protein has been demon-
strated to have constitutive activity independent of growth
factor stimulation [45, 46, 48, 49], a likely explanation of
the previously described autonomous hematopoietic colony
formation [45–48, 53] and hypersensitivity to growthfactors
on in vitro testing of cells from patients with multiple MPNs
[45, 47, 48, 54]. JAK2V617F is present in ≈95% of patients
with PV [45, 55], and ≈40–60% with ET [45, 46, 55]a n d
PMF [45–47].
The exact mechanism of how JAK2V617F alters cell
proliferation remains to be elucidated, although multiple
components of JAK2 function have been described and
correlated with clinical features seen in the Ph- MPNs.
JAK2V617F lies in the JAK2 pseudokinase (JH2) domain,
which is an autoinhibitor of basal kinase function [56, 57].
Mutations within this domain lead to loss of autoinhibition
and constitutive kinase activity [46, 58]. One of the predom-
inant functions of JAK2 is the binding to and stabilization
of homodimeric type I cytokine receptors, which have
no kinase activity without this interaction. The receptors
for erythropoietin (EPO-R), thrombopoietin (MPL), and
other hematopoietic growth factors are homodimeric type
I cytokine receptors [58–60]. Thus, constitutively active
JAK2V617F, when paired with a homodimeric cytokine
receptor, can lead to constitutive activity of that receptor
independent of its ligand, leading to activation of the JAK-
STAT and PI3K pathways [46, 58, 61], which are involved in
cellproliferation andapoptosis, respectively. Thisinteraction
between JAK2 and homodimeric cytokine receptors may
also be one reason for the phenotypic variation amongst
patients with JAK2V617F, as the nature and frequency of
these coreceptors on cells carrying JAK2V617F may impact
the phenotypic expression of disease.
Another potential underlying cause of the phenotypic
diversity seen in JAK2V617F positive MPNs lies in the
concept of allele burden. In general, JAK2V617F positive
patients with ET have higher hemoglobin levels, lower
plateletcounts,and higherleukocytecountsthan those with-
out the mutation [62, 63]. Among those with JAK2V617F,
a large spectrum exists as to the percentage of cells actually
carrying the mutation, and this variation in allele burden
has been correlated with diﬀerences in clinical phenotype.
Patients with ET have the lowest allele burden, those with
PV and PMF an intermediate one, and those with secondary
myeloﬁbrosis the highest burden [63–65]. Similarly, patients
with PV are more likely to be homozygous for JAK2V617F,
as 32% of patients were homozygous in one large case series;
this is compared to only 2% of ET patients in the same series
[66]. The role this variation in allele burden plays in other
clinical manifestations of disease remains unclear.
Many unknowns remain as to the role of JAK2V617F
mutationsintheMPNs,especiallygiventhewidephenotypic
variation mentionedabove,thefact thatJAK2V617F is found
rarely in other myeloid disorders [67, 68], and evidence
that JAK2V617F may be a late occurrence in these disease,
following a diﬀerent, as yet unknown, causative mutation
[69–71].
Giventheseunanswered questionsregardingJAK2V617F,
much eﬀort has focused on identifying diﬀerent mutations
that may play a role in the Ph- MPNs. Multiple diﬀerent
mutations in exon 12 of the JAK2 gene have been described
and are detected in the majority of PV patients who lack the
V617F mutation[72–74]. Althoughless well described, these
mutations are also felt to interfere with the autoinhibitory
function of JAK2 [75]. Multiple activating mutations in exon
10 of the MPL gene, which codes for the TPO receptor,
have also been described [76, 77]. The prevalence of MPL
m u t a t i o n si sa p p r o x i m a t e l y5 – 7 %o fp a t i e n t sw i t hP M Fa n d
1–4% of ET patients [78, 79]; these mutations have not
been described in patients with PV. MPL mutations have
been detected concomitantly with JAK2V617F,a l t h o u g h
the percentage of Ph- MPN patients harboring a MPLThrombosis 5
• Bone marrow trilineage myeloproliferation
• Subnormal serum erythropoietin level
• Endogenous erythroid colony growth
•Platelet count ≥450 ×109/L
• Megakaryocyte proliferation with large and mature morphology
• Presence of JAK2 V617F or other clonal marker and no evidence
of reactive thrombocytosis
• Megakaryocyte proliferation and atypia accompanied by reticulin
and/or collagen ﬁbrosis; or in the absence of overt ﬁbrosis, the
megakaryocyte changes must be accompanied by increased
primary myeloﬁbrosis)
other myeloid neoplasm
• Presence of JAK2 V617F or other clonal marker and no evidence
of reactive marrow ﬁbrosis
Primary myeloﬁbrosis minor criteria
• Leukoerythroblastosis
• Increased serum lactate dehydrogenase
• Anemia
• Palpable splenomegaly
Polycythemia vera major criteria
• Hemoglobin >18.5g/dL (men) >16.5g/dL (women)‡
• Presence of JAK2 V617F or similar mutation
Polycythemia vera minor criteria
‡ Hemoglobin or hematocrit values above the 99th percentile of the
reference range for age, sex, or altitude of residence; or red cell mass >25%
above mean normal predicted or hemoglobin >17g/dL (men), or >15g/dL
(women) if associated with a sustained increase of ≥2g/dL from baseline that
cannot be attributed to correction of iron deﬁciency.
Diagnosis of polycythemia vera requires meeting either both major criteria
and one minor criterion or the ﬁrst major criterion and two minor criteria
Essential thrombocythemia major criteria
• Not meeting WHO criteria for CML, PV, PMF,
MDS or other myeloid neoplasm
Diagnosis of essential thrombocythemia requires meeting all four major criteria
Primary myeloﬁbrosis major criteria
marrow cellularity and granulocytic proliferation (i.e., preﬁbrotic
• Not meeting WHO criteria for CML, PV, MDS, or
Diagnosis of primary myeloﬁbrosis requires meeting all three major criteria and two minor criteria
Figure 2: 2008 WHO diagnostic criteria for PV, ET, and PMF. CML: chronic myelogenous leukemia; ET: essential thrombocythemia; MDS:
myelodysplastic syndrome; PMF: primary myeloﬁbrosis; PV: polycythemia vera.
mutation is higher in those without a JAK2 mutation [78].
Patients with MPL mutations do have a slightly diﬀerent
clinical phenotype, as they typically have lower hemoglobin
levels and higher platelet counts than those without MPL
mutations [80].
Another gene of interest in the MPNs is TET2,a
putative tumor suppressor gene located on chromosome
4q24. Mutations of TET2 have been detected in a variety
of myeloid disorders, including Ph- MPNs. Approximately
13% of Ph- MPN patients harbor a TET2 mutation [81],
and it appears to be more common in patients >60 years
old [82]. Clonal analysis also suggests that TET2 mutations
can occur prior to or following JAK2 mutation in patients
where the two mutations exist concomitantly,indicating that
TET2 mutation is not a prerequisite for JAK2 mutation [83].
Althoughtherole of testing fornovel mutationssuch as MPL
and TET2 as part of the diagnostic evaluation for the Ph-
MPNs is less clear than that of JAK2 evaluation, testing for
these mutations has been shown to increase sensitivity when
utilizing the WHO diagnostic criteria [84].
Even as the utility of molecular data in the diagnosis
of Ph- MPNs increases, the diversity of disease present in
the face of these mutations has required the diagnosis of
the Ph- MPNs to remain primarily a clinical one, based on
the 2008 WHO guidelines [42], summarized in Figure 2.
Diagnosis of PV is based on the demonstration of increased
redbloodcellvolume,depressedserumerythropoietinlevels,
and the presence of a clonal marker (JAK2 mutation)
[85]. Thrombocytosis is also present in ≈50% of cases
of PV [86], and the presence of thrombocytosis in the
absence of fever or infection is a minor criterion in the
Polycythemia Vera Study Group diagnostic criteria for PV
[86]. Although thrombocytosis is not a part of the WHO
diagnostic criteria for PV, its presence, especially in the
setting of evidence of elevated red cell volume, is entirely
consistent with the diagnosis. Thrombocytosis can also be
the only hematologic manifestation of PV, as the expected
erythrocytosis can be masked by volume expansion or
concomitant iron deﬁciency [87–89]. Diagnosis of PMF is
based on the presence of typical ﬁndings on bone marrow
biopsy, most notably reticulin ﬁbrosis and megakaryocytic
proliferation. Thrombocytosis is present in ≈30% of PMF
patients at diagnosis, with this number decreasing as the
disease progresses and splenomegaly often leads to throm-
bocytopenia[90]. Diagnosis of essential thrombocythemia is
essentially one of exclusion when no other diagnosis can be
made in the setting of persistent clonal thrombocytosis.
2.ThromboticComplications
Reactive thrombocytosis is generally felt thought to be a
self-limited process which resolves with resolution of the6 Thrombosis
underlying disorder when possible. The risk of thrombotic
complications with reactive thrombocytosis is felt to be
low, as 1.6% of patients with reactive thrombocytosis had
thrombotic complications in one large case series [4]. All
of these thrombotic events were venous in location and
occurred in patients with other risk factors (postoperative
setting or underlying malignancy). Even in cases of extreme
reactivethrombocytosis, therisk ofthromboticcomplication
is relatively low (4–6%) [91, 92], although reactive thrombo-
cytosis has been shown to be an independent risk factor for
thrombosis in patientsotherwise at high risk for thrombosis,
includingtraumapatients[93]andfollowingcoronaryartery
bypass grafting [94]. Patients in these settings have many
other concurrent prothrombotic risk factors which likely
contribute as much if not more to thrombotic risk than the
presence of reactive thrombocytosis.
In clonal thrombocytosis, especially in ET and PV,
thrombotic complications are a major cause of morbidity
and mortality and the primary factor in determining treat-
ment strategy. Although thrombosis can be an issue in other
causes of clonal thrombocytosis, it is most common and
most thoroughly investigated in PV and ET, and thus these
diseases will be the focus of discussion.
2.1. Microvascular Thrombotic Disease. Many patients with
clonal thrombocytosis will experience vasomotor symptoms
including headache, syncope, chest pain, erythromelalgia,
acrocyanosis, and visual changes. These symptoms are dueto
microvascular inﬂammation, platelet aggregation and arteri-
olarmicrothrombiformation[95,96]andar emor ecommon
in ET than PV, with some vasomotor symptoms present
in 29–40% of ET patients at presentation [97–99]. The
frequency of erythromelalgia, the most common vasomotor
complication of PV and ET, is not directly correlated with
higher platelet counts, and in fact, vasomotor symptoms
are essentially never present in reactive thrombocytosis.
These facts underlie the important role that qualitative
platelet abnormalities [96] and increased thromboxane-
induced platelet activation [100] play in causing vasomotor
symptoms, as erythromelalgia has been described in patients
with relatively normal platelet counts in a multitude of non-
hematologic conditions [101]. The lack of speciﬁcity ofthese
symptoms makes estimating prevalence diﬃcult, but the
typical prompt response of ET-related vasomotor symptoms
to aspirin can be a useful diagnostic as well as therapeutic
intervention.
2.2. Macrovascular Thrombotic Disease. T h er a t eo fm a c r o -
vascular thrombotic complications at diagnosis ranges 11–
25% in ET and 12–39% in PV [102–106], with arterial
thrombosis comprising the majority of events. The cere-
brovascular circulation, either in the form of stroke or
transient ischemic attack,is the most common site of arterial
thrombotic disease, followed by the coronary arteries and
peripheral vasculature [102, 105, 107, 108]. The arterial pre-
dominance of thrombotic events is more marked in ET than
in PV, where up to ≈40% of thrombotic events are venous
in nature [102, 105, 109]. Of special signiﬁcance are venous
thromboses inunusual locationssuch asthesplanchnic veins
and cerebral sinuses, as >50% of venous thrombotic events
in PV and ET occur in these locations [110, 111]; this is
especiallytrueinyoungerpatients[112].Giventhefrequency
of thrombotic events in these unusual locations, strong
consideration should be given to evaluation for occult Ph-
MPN in any patient presenting with splanchnic or cerebral
sinus thrombosis. Case series have reported that 23–51% of
patients suﬀering from splanchnic thrombosis without any
other risk factors can be diagnosed with an underlying Ph-
MPN at the time of thrombosis [113, 114], and JAK2V617F
mutations have been demonstrated in a number of such
patients, many of which only met full criteria for a Ph- MPN
later in their course [115, 116].
The risk for thrombosis does not stop with diagnosis,
and large case series have demonstrated a signiﬁcant risk
of thrombotic events following diagnosis even in patients
treated with cytoreductive and antiplatelet therapy. Wolan-
skyj et al. compiled a historic cohort of 322 patients with ET
with 70% having >10 years of followup [106]. In this cohort,
26% of patients presented with evidence of thrombosis;
the cumulative probability of thrombosis at 5, 10, and 20
years was 32%, 42%, and 52%, respectively. 82% of these
patients received cytoreductive therapy and 62% received
aspirin as part of their treatment regimen. Similarly, in a
large series of 1213 Italian patients with ET [105] 34% of
patients either presented with thrombosis (20%) or had a
history of thrombosis prior to presentation (14%). After a
median of 5 years of followup, an additional 19% of patients
had suﬀeredathromboticevent,with acumulativeincidence
of thrombosis of 53%.
2.3. Risk Factors for Thrombosis. Age is a signiﬁcant risk
factor for thrombosis in the general population [117],
and multiple diﬀerent epidemiologic studies have shown
increasing risk for thrombosis in PV and ET with increasing
age [102, 105–107]. Another consistently demonstrated risk
factor for thrombosis in patients with PV and ET is a prior
thrombotic event [98, 102, 105–107]. The combination of
age >65 and a prior thrombotic event is associated with
a markedly increased risk of thrombosis in PV, with a
thrombosis rate in the European Collaboration on Low-
Dose Aspirin in Polycythemia Vera (ECLAP) trial of 10.9
events/100 persons/year as compared to 2.5 events/100
persons/year in those without either risk factor [102].
Another more recently described independent risk factor
for thrombosis in PV and ET is leukocytosis [106, 118–
120].Theprecisemechanisms behindthisassociation arenot
entirely clear, although it is likely that qualitative leukocyte
abnormalities play as large a role as quantitative increases
in these diseases. The relative importance of qualitative
leukocyte abnormalities is also supported by the fact that
patients with CML, who typically have the highest leukocyte
countsofalltheMPNs,haveamuchlowerrateofthrombosis
than any of the Ph- MPNs [121]. Activated granulocytes
are known to play an important role in platelet activation
and endothelial injury [104], and patients with ET and
PV have evidence of increased granulocyte activation asThrombosis 7
compared to normal controls [122]; an association between
JAK2V617F and constitutive activation of granulocytes has
also been suggested [64]. Another feature of this increased
risk which speaks to a qualitative component is the degree
of leukocytosis which confers an excess risk. Multiple series
have shown that a leukocyte count of >8.7 × 109/L, well
withinthenormalrange,isassociatedwithexcessthrombotic
risk in both PV and ET [118, 120], with ROC analysis
in one study showing a leukocyte count of 9.4 × 109/L
having the best sensitivity and speciﬁcity for demarcating
high-and low-risk patients [118]. The implications of this
association in regards to treatment of these disorders remain
controversial, although it may provide a rationale for the
eﬃcacy of cytoreductive therapy and a leukocyte count
of <10 × 109/L has been integrated into recently revised
European LeukemiaNet response criteria for PV and ET
[123].
In contrast to the increased risk in leukocytosis, an
increased risk of thrombotic events with increasing platelet
count has not been consistently demonstrated. Multiple
studies have failed to show a direct correlation between
increasing platelet count and thrombotic risk [91, 107,
124], although ≈80% of thrombotic events occur in those
with a platelet count >600 × 109/L [125]. Cytoreductive
therapy leading to decreased platelet counts has been
shown to decrease microcirculatory vasomotor symptoms
and thrombosis [95, 125, 126], but it is unclear if this
is directly due to decreases in the platelet count or to
other eﬀects of cytoreductive therapy such as a decrease in
leukocyte count. Likely more important than the absolute
numberofplateletsarethemultiplequalitativeabnormalities
which have been noted in PV and ET, including decreased
response to adenosine diphosphate and epinephrine [103,
127] altered glycoproteinreceptors [127, 128], and the excess
thromboxane production noted in the Ph- MPNs, leading to
increased platelet activation [100, 129].
The roleoferythrocytosisasanindependentrisk factoris
similarly complex. Multiple studies have shown that increas-
ing hematocrit is associated with increasing blood viscosity
and thrombotic risk [130], with the cerebral circulation
being especially vulnerable [131]. Increasing viscosity leads
to a displacement of platelets to the periphery of arterial
blood ﬂow under high shear stress conditions [132], leading
to greater interaction between platelets as well as platelets
and the underlying endothelium. Many patients with PV
also have an elevated number of platelets with the above-
mentioned qualitative abnormalities, and bringing these
platelets in closer contact with each other and the vessel wall
isonelikelyreason fortheincreaseinarterial thromboticrisk
in these patients. These functional platelet abnormalities,
as well as qualitative red blood cell (RBC) abnormalities
including increased RBC adhesion to endothelial cells [133],
likely play an important role in thrombosis in PV and ET, as
animal models have failed to show hyperviscosity alone as a
signiﬁcant risk factor for thrombosis [134].
Evaluation of the role of traditional cardiovascular risk
factors tothrombotic risk in PV and ET has led toconﬂicting
results, with some studies suggesting increased risk with
hypercholesterolemia [107]a n ds m o k i n g[ 135] while others
haveshown no increased risk with any known cardiovascular
risk factors [106, 124].
The discovery of the JAK2V617F mutation has led to
extensive evaluation to determine whether those carrying
this mutation have a diﬀerent disease phenotype than those
who are JAK2 wild type, and this evaluation has included
examining the risk of thrombosis in both groups. A theoret-
ical basis for an increased risk of thrombosis in PV and ET
lies in the fact that the increased RBC-endothelial adhesion
mentioned above is felt to be mediated by a JAK2V617F-
mediated mechanism [133]. Thus far, the implications of
JAK2V617F mutation on thrombosis risk are unclear, with
multiple retrospective studies indicating an increased risk
of thrombosis in ET [136–138], while others have failed to
show such an association [118, 139]. A recent meta-analysis
of 21 studies in ET patients suggested an increased risk of
increased risk of thrombosis (OR 1.92, 95% CI 1.45–2.53)
in those with JAK2V617F mutations [140]; the increased
risk was for both venous and arterial thromboses. Other
groups have examined increasing JAK2 allele burden as a
risk factor for thrombosis and a potential reason for the
conﬂicting results regarding the impact of JAK2 mutations
on thrombotic risk. Analysis of 639 patients with ET and
323 with PV by Vannucchi et al. reported an increased risk
of thrombosis (both arterial and venous) in the small per-
centageofETpatientswho werehomozygousforJAK2V617F
(hazard ratio 3.97, 95% conﬁdence interval [CI] 1.34–
11.7) compared with JAK2 wild-type patients [66]. No such
diﬀerence was present in patients with PV and other studies
have not demonstrated this increased risk in ET patients
[118].
The impact of MPL mutations on thrombotic risk has
been less well evaluated and is diﬃcult given the small
number of patients with these mutations and its frequent
cooccurrence with JAK2 mutations. In the small number of
studies evaluating thrombotic risk in these patients, MPL
mutation does not appear to be an independent risk factor
for thrombosis [78, 80].
3.Bleeding Risk
Aparadoxicalriskofbleedinghasbeennotedinpatientswith
thrombocytosis, especially extreme thrombocytosis [91, 98],
and bleeding in this setting is usually mucocutaneous in
nature. This excess risk is likely multifactorial; in clonal
thrombocytosis, platelet function abnormalities no doubt
play a major role. Another potential cause of bleeding
regardless of the cause of thrombocytosis is acquired von
Willebrand’s syndrome (AVWS) due to increased adsorption
of large von Willebrand factor (vWF) multimers [141, 142]
by the abnormally high number of circulating platelets.
Testing for AVWS can be undertaken in patients with
thrombocytosis and bleeding to evaluate for a decrease
in large vWF multimers, and in patients with extreme
thrombocytosis, evaluation for AVWS can be incorporated
intotheriskstratiﬁcationofotherwiselow-riskpatientsprior
to the initiation of antiplatelet therapy.8 Thrombosis
4.Treatmentof Thrombocytosis
4.1. Reactive Thrombocytosis. Reactive thrombocytosis, as
mentioned above, is felt to be self-limited with little excess
associated thrombotic risk. Because of this lack of throm-
botic risk as well as a theoretical risk of paradoxical bleeding,
no antiplatelet therapy is recommended, even for extreme
thrombocytosis. The occurrence of thrombosis in patients
felt to have reactive thrombocytosis may be reason to under-
take evaluation for a concomitant clonal thrombocytosis,
especially with splanchnic or cerebral thrombosis.
In patients who present with extreme thrombocytosis
of unknown etiology and evidence of active bleeding or
critical thrombosis, plateletpheresis can provide a rapid
reduction in platelet count while the diagnostic evaluation
is undertaken [143, 144]. In patients where a clonal cause
of thrombocytosis is known or suspected, cytoreductive
therapy (discussed below) can also be initiated at high doses
for additional rapid platelet-lowering eﬀect [145].
4.2. Clonal Thrombocytosis. Treatment strategies in PV and
ET are focused on reducing the risk of thrombotic events in
those at risk for them, as thrombosis is the most common
complication leading to morbidity and mortality in these
disorders. Treatments to this end fall into essentially two
categories: cytoreductive therapy with an aim to decrease
circulating platelet count (as well as hematocrit in PV) and
antiplatelet therapy, usually in the form of aspirin. Given
these treatment approaches, much work has been done in
an eﬀort to risk-stratify patients to determine which patients
will beneﬁt from either or both of the above classes of
therapy. Risk assessment and subsequent therapy based on
risk of thrombosis has led to a variety of treatment strategies
based on risk (Figures 3 and 4).
4.3. Essential Thrombocytosis. In ET, multiple retrospective
studies have consistently described age >60 and a prior
thrombotic event as risk factors for thrombosis [98, 106,
107]. Patients meeting either of these criteria are generally
considered to be in a “high risk” group and felt thought
to beneﬁt from both antiplatelet and cytoreductive therapy.
This approach is supported by multiple randomized clinical
trials. The ﬁrst, by Cortelazzo et al. [126]p r o s p e c t i v e l y
evaluated 114 patients with ET who met the above high-risk
criteria. Patients were randomized to receive hydroxyurea
(HU), an antimetabolite which primarily acts in S phase
and is eﬀective in reducing platelet counts in ET, versus
no cytoreductive therapy. HU dose was titrated to maintain
a platelet count <600 × 109/L and after a median of 27
months of followup, 3.6% of patients receiving HU had
suﬀered a thrombotic event,compared to 24% in the control
group, a statistically signiﬁcant diﬀerence. It should be noted
that 69% of patients were on some form of antiplatelet
therapy (aspirin or ticlodipine), and use of these agents
was similar in the two treatment groups. Whereas this
trial demonstrated the beneﬁt of cytoreductive therapy,
the Medical Research Council primary thrombocythemia-1
(PT-1) trial [146] aimed to determine the best method of
cytoreduction, comparing the use of HU with anagrelide.
Anagrelide is an orally active quinazolinone derivative which
was initially developed as an inhibitor of platelet aggregation
but has also been shown to reduce platelet count with little
eﬀect on other hematopoietic cell lines through blockade of
megakaryocyte diﬀerentiation and proliferation[147].Inthe
PT-1 trial, a total of 809 patients who met high-risk criteria
(deﬁned as any of the following: age >60 years, prior throm-
bosis, hypertension or platelet count >1,000 × 109/L) were
randomized to receive low-dose aspirin plus either HU or
anagrelide titratedtomaintain aplateletcount<400 × 109/L.
Patients randomized to HU + aspirin had a signiﬁcantly
lower rate of arterial thrombosis, major hemorrhage, and
transformation to myeloﬁbrosis, but signiﬁcantly higher risk
of venous thrombosis. There were no diﬀerences in control
of platelet count in the two groups, and the overall risk of
thrombosis after a median of 39 months of followup was
7.6% in the HU group compared to 10.1% in the anagrelide
group.
These results have led to widespread adoption of HU +
aspirin as ﬁrst-line therapy in patients with high-risk ET.
Anagrelide + aspirin does appear to have beneﬁt in reducing
thrombotic events in patients in ET, if one compares
thrombotic rates in the PT-1 trial with that of the study
by Cortelazzo et al. [126] and other historic controls.
Thus, anagrelide continues to have an important role in
the treatment of ET, especially when toxicities such as
cytopenias or cutaneous lesions limit the use of HU. There
is growing evidence that combination therapy with HU
and anagrelide can be eﬀective in treating patients either
refractory to or intolerant of large doses of HU [148].
Comparedtotreatmentwithanagrelidealone,thiscombined
approach allows forcontinuationofreduceddoseHU,which
may allow for continued leukocyte reduction, which likely
contributes at least a portion of the protective beneﬁt of HU
treatment.
Goals of treatment in high-risk ET are primarily deﬁned
in terms of reduction in platelet count, with a goal of<400 ×
109/L being a common target given the ﬁndings of the PT-
1t r i a l[ 146]. Patients in the study by Cortelazzo et al. [126]
had a targeted platelet count of<600 × 109/L, indicating that
a slightly relaxed platelet goal may still allow for beneﬁt in
cytoreductive therapy in those unable to maintain a platelet
count of <400 × 109/L. The recently published European
LeukemiaNet response criteria for ET [123] include many
other factors, with complete response deﬁned as (1) platelet
count <400 × 109/L, (2) no disease-related symptoms, (3)
normal spleen size on imaging, and (4) white blood cell
count <10 × 109/L. Partial response is deﬁned as platelet
count <600 × 109/L or a decrease of >50% from baseline.
The utility of these criteria in decision-making regarding
treatment strategies in ET is yet to be determined.
Growing evidence supports the concept that patients
with ET who do not meet high-risk criteria do well with
less aggressive therapy. Rugerri et al. [149]p r o s p e c t i v e l y
followed 65 patients <60 years old with no thrombosis
history and a platelet count <1500 × 109/L, and the
thrombosis rate in this cohort (1.91/100 patient-years) was
not signiﬁcantly diﬀerent than that of age and sex-matchedThrombosis 9
Essential thrombocytosis
• Individualized risk assessment
Age >60
Prior thrombosis
(?) Platelet count >1500 ×109/L
• Hydroxyurea
• Goal platelet count <400 ×109/L
• Low dose aspirin
(unless contraindicated)
Refractory/intolerant
Relax goal platelet count to 600 ×109/L
Combination therapy with anagrelide
Other agent(s):
• IFN-alpha (pregnancy)
•
•
32P (in elderly)
Clinical trial
Low risk: (Age <60; no prior
thrombosis)
Leukocyte count
JAK2 mutation status
Other vascular risk factors
Low-dose aspirin
Vasomotor
symptoms
Consider low-dose aspirin based on
individual patient risk proﬁle
High risk:
Cytoreductive therapy
And
Antiplatelet therapy
Secondaryriskassessment:
ﬁrst-line agent
Figure 3: Treatment algorithm for ET.
controls (1.5/100patient-years). Aspirin was used only in the
event of microvascular symptoms; less than 25% of patients
in both arms received aspirin during the median 4.1 years of
followup.
Antiplatelet therapy, most commonly aspirin, also plays
an important role in the treatment of ET, and its eﬃcacy
in the treatment of microvascular complications has been
well established [95, 96]. Its role in the prevention of
macrovascular complications is less clear. Retrospective eval-
uation suggests antiplatelet therapy may reduce thrombotic
complications in a high-risk population [124, 150], but
randomized data is lacking. Further support for the use of
antiplatelet therapy in ET has been extrapolated from the
ECLAP trial, which demonstrated a signiﬁcant reduction in
vascular events in low and intermediate risk PV patients
treated with aspirin as compared to placebo [151].
The role of antiplatelet therapy in a low-risk ET popu-
lation was recently examined in a retrospective evaluation
of 300 Spanish patients by Alvarez-Larran et al. [152].
Rates of thrombosis were not signiﬁcantly diﬀerent in
those treated with antiplatelet therapy and those followed
with observation; subgroup analysis did demonstrate that
patients harboring the JAK2V617F mutation did have a
signiﬁcantly increased rate of venous, but not arterial
thrombosis. Patients with cardiovascular risk factors who
were observed without antiplatelet therapy also had a higher
rate of arterial thrombosis compared to those receiving
aspirin. Patients with a platelet count of >1000 × 109/L
treated with antiplatelet therapy had a signiﬁcantly increased
risk of bleeding. These data reinforce the importance of a
thorough, individualized approach to risk assessment in ET
patients prior to determining a treatment strategy.
4.4. Polycythemia Vera. The foundation of therapy in poly-
cythemia vera is therapeutic phlebotomy to maintain a
hematocrit <45% in men and <42% in women (Figure 4).
Thisapproachisbasedonthephlebotomystrategyutilizedin
multiple randomized PVSG studies that demonstrated phle-
botomy alone was associated with equivalent or improved
survival when compared to phlebotomy plus additional
agents such as busulfan, 32P, and chlorambucil [153, 154].
Addition of these agents was consistently associated with
increased risk of late hematologic complications, especially
acute myeloid leukemia. Treatment with phlebotomy alone,
however, was associated with a relatively high risk of
thrombosis in these studies, especially early in the course of
therapy, with thrombosis rates of 23% in the ﬁrst two years.
In an eﬀort to address this early thrombotic risk, a
subsequent Phase II PVSG trial including 51 patients added
HUto phlebotomy with a goal hematocrit <50%and platelet
count <600 × 109/L. The thrombotic rate seen in the ﬁrst
2 years of therapy was 9%, signiﬁcantly lower than the 23%
noted in the earlier PVSG trial [155]. The risk of leukemic
transformation in this cohort was 6% and not signiﬁcantly10 Thrombosis
All patients:
• Phlebotomy (goal HCT <42% in women,
<45% in men)
• Low dose aspirin (unless contraindicated)
• Individualized risk assessment
Age >60
Prior thrombosis
Low risk: (Age <60; no prior thrombosis)
No cytoreductive therapy
Consider hydroxyurea or other
cytoreductive agent based on toxicity
proﬁle
Polycythemia vera
High risk:
OR
Figure 4: Treatment algorithm for PV.
diﬀerent than that seen in the phlebotomy only arm of
earlier PVSG studies, but the leukemogenic risk of HU is
stillhotlydebated[156–158].NophaseIIIstudiescomparing
HU + phlebotomy with phlebotomy alone in PV have been
performed, but the results of this Phase II study have led to
the common use of HU in addition to phlebotomy in those
considered high risk for thrombosis (Age >60 and/or prior
thrombosis) [159].
The use of antiplatelet therapy in PV was initially
thoughttobeassociatedwithpooreroutcomesandincreased
bleeding risk based on an early PVSG study [160]. This
protocol, however, utilized a total dose of 900mg of aspirin
daily along with dipyridamole, another antiplatelet agent.
Subsequentstudieshavedemonstrated theeﬃcacyand safety
of lower doses of aspirin therapy in PV. A Gruppo Italiano
S t u d i oP o l i c i t e m i aV e r as t u d y[ 161] randomized 112 PV
patients to receive either aspirin (40mg/day) or placebo.
The low dose aspirin was well tolerated, led to a signiﬁcant
decrease in serum thromboxane B2 levels, and was not
associated with an increased risk of bleeding. The ECLAP
trial [151] randomized 518 patients who had no other
indication for antiplatelet therapy to low-dose aspirin or
placeboand demonstratedsigniﬁcant reductionintheriskof
nonfatal myocardial infarction, nonfatal stroke, pulmonary
embolism, deep venousthrombosis, and death. Bleeding risk
was not signiﬁcantly diﬀerent in the two treatment groups.
These data have led to recommendations for use of low-dose
aspirin inall patientswith PV, regardless ofrisk, exceptinthe
face of contraindication.
Other agents, such as interferon alpha [162, 163]a n d ,i n
Europe, pipobroman [164, 165] have also been used in the
treatment of both ET and PV. The use of these therapies is
generally limited to those who have failed or are intolerant
of more standard therapy; interferon alpha is generally
considered the therapy of choice in pregnant patients
requiring cytoreductive therapy given its low teratogenicity
[166]. A variety of JAK2 inhibitors have been evaluated
in preclinical studies in the Ph-MPNs and are currently
progressing through clinical trials [167, 168]; the majority
of patients enrolled in JAK2 inhibitor trials to this point
havehad PMF. Resultshavebeenpromising, andfurther trial
results and evaluation of new potential therapeutic agents
may lead to a paradigm shift in the treatment of all the
MPNs, including ET and PV.
5.Conclusion
Thrombocytosis exists in the setting of a variety of clinical
situations and can have widely diverse underlying etiologies.
Clonal thrombocytosis is often due to one of the Ph- MPNs,
and in this setting, the risk of thrombosis is great and
should be the primary factor guiding treatment strategy. The
mechanisms underlying this increased thrombotic risk are
not yet fully understood, and the role of risk factors such
as JAK2 status and leukocytosis has yet to be conclusively
established. Integration of these and other risk factors into a
risk-based treatment decision model should allow for better
patient selection for cytoreductive therapy. The ongoing
discovery and description of new molecular abnormalities in
these disorders should allow for advances in both diagnosis
and treatment of clonal thrombocytosis.Thrombosis 11
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